Bristol Myers Squibb (BMY) said its tender offer to acquire all of the outstanding shares of RayzeBio, Inc. (RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired on February 22, 2024. As of the expiration time, approximately 53,052,499 shares of RazyeBio common stock were validly tendered and not validly withdrawn pursuant to the offer, representing approximately 86% of the issued and outstanding shares of RayzeBio common stock.
The companies expect the transaction to close on February 26, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.